News & Comment

An inventor looking for seed funding should take some time to understand the common attitudes and behaviors of angel investors.

The country's government aims to promote the commercialization of publicly funded research and to boost private investment into its nascent biotech sector.

Venture capital interests shift to platform technologies.

Budding bioentrepreneurs need an information-gathering strategy that balances time and budgetary constraints when deciding whether to sift through the glut of free information on biotech or to opt for subscription services offering higher quality, more insightful analysis.

Budding bioentrepreneurs should try to attain seed funds from both angel investors and venture capitalists in tandem.

Heavy workload, high staff turnover and poor marketing practices have hampered transfer of technologies from the National Institutes of Health to industry.

A new report provides details of the current state of VC funding for UK university spinouts and suggestions for how to reverse the trend.

Howard Bremer, whose career has tracked with and influenced the development of university technology transfer initiatives, reflects on his path and where it has led both him and the evolving debate over use of federally funded inventions.

Many biotech companies are founded by scientists. But there is certainly a path, somewhat less trodden but nonetheless viable, for the inspired entrepreneur who may not be a brilliant researcher.

Drawing on a strong research base, the country seeks to provide better incentives for commercialization.

Regional biotech industry groups throughout Germany are cooperating with each other to enhance the international competitiveness of the country's biotech sector.

As a UK-Texas collaboration gets ready to launch its first biotech firm, many regional industry organizations see the future of startups in such programs.

As big pharmas fall over each other to proclaim themselves the 'partner of choice' for biotechs, there are still some lessons the younger sibling can learn.

But the country still needs a larger R&D budget and a better developed infrastructure to strengthen its biotech sector.

Cash awards have persuaded 25 promising scientists to settle in Europe, but other barriers to fostering bioentrepreneurs in the EU remain.

Members of the drug industry debate the effects of a proposed law in Switzerland that would limit the patent protection of gene sequences.

For biotech startups, securing loans for equipment early on can ease financial worries down the road.

Initiatives are popping up across the Middle East to promote biotech research and commercialization.

Venture capital investment into European biotechs doubled in the last quarter, but US firms still raise more in an average round.

Scientists in Russia seek overseas partners to commercialize their inventions, but the country's immature business climate often stands in the way.